Point-of-care testing (POCT) has a profound impact on healthcare by offering rapid and convenient diagnostic solutions. It is extensively used in clinical settings, emergency departments, and remote or underserved areas for on-the-spot testing. POCT aids in early disease detection, monitoring chronic conditions, and making timely treatment decisions. It also reduces the need for laboratory-based testing, resulting in quicker results and improved patient outcomes. Its versatility makes POCT invaluable in managing conditions such as diabetes, infectious diseases, cardiac issues, and more.
Access Full Report @ https://www.databridgemarketresearch.com/reports/apac-point-care-testing-poct-market
Data Bridge Market Research analyses that the Asia-Pacific Point-Of-Care Testing (POCT) Market which was USD 29 billion in 2021, is expected to reach USD 64.46 billion by 2029, and is expected to undergo a CAGR of 10.5% during the forecast period 2022 to 2029. Government initiatives and approvals for rapid diagnostic devices bolster market growth by fostering a conducive regulatory environment and encouraging innovation. This support expedites the development and adoption of point-of-care testing solutions, enhancing healthcare accessibility and outcomes.
Key Findings of the Study
Remote and underserved areas are expected to drive the market's growth rate
Point-of-care testing (POCT) is crucial in regions with limited healthcare facilities, as it provides immediate diagnostic capabilities. In areas lacking access to well-equipped hospitals or laboratories, POCT devices offer on-the-spot testing, allowing for quicker disease identification, treatment, and intervention. This reduces the burden on centralized healthcare facilities and healthcare professionals, enhancing overall healthcare access and quality in remote or underserved regions, ultimately improving health outcomes and bridging healthcare disparities.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Pregnancy and Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products, Rapid Coagulation Testing and Other POC Products), Application (Blood Transfusion, Cardiac Monitoring, Coagulation, Blood Glucose, Haematology, Non- Invasive SPO2 Monitoring, Non- Invasive PCO2 Monitoring, Whole Blood Analysis, Vital Sign Monitoring and Others), Platform (Lateral Flow Assays/Immunochromatography Tests, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays), Prescription Mode (Prescription-Based Testing and OTC Testing), Testing Type (Immunoassays, Cell-Based Assays, Nucleic Acid Amplification Testing, Clinical Chemistry Assays and Hematology), End-User (Hospitals, Clinics, Laboratories, Home Care, Ambulatory Surgery Centers and Others), Distribution Channel (Direct Tender and Retail Pharmacies)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)
|
|
Market Players Covered
|
Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Siemens Healthcare Private Limited (Germany), Bio-Rad Laboratories, Inc. (U.S.), Danaher (U.S.), Sekisui Diagnostics (U.S.), Trinity Biotech (Ireland), bioMérieux (France), EKF Diagnostics (Germany), AccuBioTech Co., Ltd. (China), Instrumentation Laboratory (U.S.), Beckman Coulter, Inc. (U.S.), PTS Diagnostics (U.S.), Nova Biomedical (U.S.), Chembio Diagnostics, Inc. (U.S.), Quidel Corporation (U.S.) and Sienco, Inc (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Asia-Pacific point-of-care testing (POCT) market is segmented on the basis of product, testing type, prescription, platform, application, end-user, and distribution channel.
- On the basis of product, the Asia-Pacific point-of-care testing (POCT) market is segmented into glucose monitoring products, cardiometabolic testing products, infectious disease testing products, pregnancy and fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, fecal occult testing products, rapid coagulation testing, and other POC products
- On the basis of testing type, the Asia-Pacific point-of-care testing (POCT) market is segmented into immunoassays, cell-based assays, nucleic acid amplification testing, clinical chemistry assays, and hematology
- On the basis of prescription, the Asia-Pacific point-of-care testing (POCT) market is segmented into prescription-based testing and OTC testing.
- On the basis of platform, the Asia-Pacific point-of-care testing (POCT) market is segmented into (lateral flow assays/immunochromatography tests, dipsticks, microfluidics, molecular diagnostics, and immunoassays.
- On the basis of application, the Asia-Pacific point-of-care testing (POCT) market is segmented into blood transfusion, cardiac monitoring, coagulation, blood glucose, haematology, non- invasive spo2 monitoring, non- invasive pco2 monitoring, whole blood analysis, vital sign monitoring, and others
- On the basis of end-user, the Asia-Pacific point-of-care testing (POCT) market is segmented into hospitals, clinics, laboratories, home care, ambulatory surgery centers, and others.
- On the basis of distribution channel, the Asia-Pacific point-of-care testing (POCT) market is segmented into direct tender and retail pharmacies.
Major Players
Data Bridge Market Research recognizes the following companies as the Asia-Pacific point-of-care testing (POCT) market players in Asia-Pacific point-of-care testing (POCT) market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Siemens Healthcare Private Limited (Germany), Bio-Rad Laboratories, Inc. (U.S.), Danaher (U.S.), Sekisui Diagnostics (U.S.).
Market Developments
- In January 2022, Roche launched the Cobas Pulse System in select countries where it received the CE Mark. This system represents Roche Diagnostics' latest generation of connected point-of-care solutions for professional blood glucose management. The CE Mark signifies compliance with European Union standards for medical devices, indicating the product's adherence to quality and safety standards. The Cobas Pulse System aims to provide advanced blood glucose monitoring solutions for healthcare professionals and patients.
- In October 2021, Thermo Fisher Scientific obtained FDA Emergency Use Authorization (EUA) for conducting COVID-19 tests with the Spectrum Solutions SpectrumDNA SDNA-1000 collection device. This high-throughput, automated testing system, integrated with the Amplitude Solution, introduced a novel saliva sample collection method for COVID-19 testing. The EUA approval marked an important step in improving COVID-19 testing capabilities, making the process more efficient and accessible to the public.
- In June 2021, the SPECIFIC REVEAL Rapid AST system was co-exclusively distributed in Europe by bioMérieux and Specific Diagnostics. This system operates in conjunction with bioMérieux's BIOFIRE BCID2, enhancing diagnostic capabilities. It allows for rapid, accurate antimicrobial susceptibility testing (AST), aiding clinicians in determining the most effective treatment for patients with bloodstream infections. The collaboration between the two companies sought to provide healthcare professionals in Europe with advanced tools for infection management.
Regional Analysis
Geographically, the countries covered in the Asia-Pacific point-of-care testing (POCT) market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
As per Data Bridge Market Research analysis:
China is the dominant region in Asia-Pacific point-of-care testing (POCT) market during the forecast period 2022-2029
China dominates the point-of-care testing (POCT) market stems from its extensive application in various healthcare sectors. POCT products find use in hospital operations, emergency departments, intensive care, chronic disease management, public health crisis response, county-level healthcare facility development, and rural healthcare support. This wide range of applications positions China as a key player in advancing POCT solutions and addressing diverse healthcare needs.
Japan is expected to dominate the Asia-Pacific point-of-care testing (POCT) market in the forecast period 2022-2029
Japan is expected to dominate the point-of-care testing (POCT) market is attributed to a rising prevalence of diseases such as HIV, leading to a greater demand for POCT devices with a high approval rate. In contrast, India's prominence is due to its substantial disease burden, driving a robust market for POCT solutions. These countries stand out as significant contributors to the global growth of POCT, catering to specific healthcare needs.
For more detailed information about the Asia-Pacific point-of-care testing (POCT) market report, click here –
